...
首页> 外文期刊>Critical reviews in oncology/hematology >Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study.
【24h】

Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study.

机译:一项肿瘤标志物可预测70岁以上患者通过一级内分泌疗法成功治疗乳腺癌的前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

We report a prospective study of women over 70 years of age with early breast cancer who had primary endocrine treatment. Core biopsies of the cancer were taken at diagnosis and assessed using immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PgR), epidermal growth factor receptor (EGFR), pS2, cyclin D1, p21, p53, HER2 and MIB1 (Ki67). Outcome analysis was performed at a median follow-up of 70 months. Correlation was sought between tumour marker measurements and disease control. When all patients were considered, a significant relationship was found between the absence of ER and PgR, the presence of p53 and EGFR, and high MIB1 and treatment failure. However, for the ER positive cancers, no other marker predicted treatment failure or relapse. There remains an important clinical need to identify those ER positive breast cancers that will not respond to endocrine treatment, and those in which the response will be short-lived.
机译:我们报告了一项对70岁以上患有早期乳腺癌且曾接受内分泌治疗的女性的前瞻性研究。在诊断时进行了癌症的核心活检,并使用免疫组织化学对雌激素受体(ER),孕激素受体(PgR),表皮生长因子受体(EGFR),pS2,细胞周期蛋白D1,p21,p53,HER2和MIB1(Ki67)进行了评估。在中位随访70个月时进行结果分析。在肿瘤标记物测量与疾病控制之间寻求相关性。当考虑所有患者时,发现不存在ER和PgR,存在p53和EGFR,高MIB1与治疗失败之间存在显着关系。但是,对于ER阳性癌症,没有其他指标可预测治疗失败或复发。识别那些对内分泌治疗无反应的ER阳性乳腺癌以及那些反应短寿的ER阳性乳腺癌仍然是重要的临床需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号